Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 6
2015 6
2016 4
2017 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
EU pharmaceutical expenditure forecast.
Urbinati D, Rémuzat C, Kornfeld Å, Vataire AL, Cetinsoy L, Aballéa S, Mzoughi O, Toumi M. Urbinati D, et al. Among authors: remuzat c. J Mark Access Health Policy. 2014 Oct 30;2. doi: 10.3402/jmahp.v2.23738. eCollection 2014. J Mark Access Health Policy. 2014. PMID: 27226837 Free PMC article.
Novel methodology for pharmaceutical expenditure forecast.
Vataire AL, Cetinsoy L, Aballéa S, Rémuzat C, Urbinati D, Kornfeld Å, Mzoughi O, Toumi M. Vataire AL, et al. Among authors: remuzat c. J Mark Access Health Policy. 2014 Nov 27;2. doi: 10.3402/jmahp.v2.24082. eCollection 2014. J Mark Access Health Policy. 2014. PMID: 27226843 Free PMC article.
Gene therapies development: slow progress and promising prospect.
Hanna E, Rémuzat C, Auquier P, Toumi M. Hanna E, et al. Among authors: remuzat c. J Mark Access Health Policy. 2017 Jan 3;5(1):1265293. doi: 10.1080/20016689.2017.1265293. eCollection 2017. J Mark Access Health Policy. 2017. PMID: 28265348 Free PMC article.
Advanced therapy medicinal products: current and future perspectives.
Hanna E, Rémuzat C, Auquier P, Toumi M. Hanna E, et al. Among authors: remuzat c. J Mark Access Health Policy. 2016 Apr 25;4. doi: 10.3402/jmahp.v4.31036. eCollection 2016. J Mark Access Health Policy. 2016. PMID: 27123193 Free PMC article.
Key drivers for market penetration of biosimilars in Europe.
Rémuzat C, Dorey J, Cristeau O, Ionescu D, Radière G, Toumi M. Rémuzat C, et al. J Mark Access Health Policy. 2017 Jan 30;5(1):1272308. doi: 10.1080/20016689.2016.1272308. eCollection 2017. J Mark Access Health Policy. 2017. PMID: 28265349 Free PMC article.
Market access pathways for cell therapies in France.
Rémuzat C, Toumi M, Jørgensen J, Kefalas P. Rémuzat C, et al. J Mark Access Health Policy. 2015 Nov 18;3. doi: 10.3402/jmahp.v3.29094. eCollection 2015. J Mark Access Health Policy. 2015. PMID: 27123176 Free PMC article.
25 results